Why the study?
Myxofibrosarcoma is a soft tissue sarcoma prevailing in the elderly associated with metastasis and mortality, but had not been reported as a non-metastatic intermediate grade presentation in the thorax.
This case highlights that myxofibrosarcoma should be considered in the assessment of chest wall tumors, and can be successfully managed with surgery and radiotherapy.
Supports including myxofibrosarcoma in chest wall tumor differentials; leaves open efficacy of surgery-radiotherapy in larger cohorts.
Myxofibrosarcoma is a soft tissue sarcoma (STS) prevailing in the elderly and is associated with metastasis and mortality. In this case, an 88-year-old male is presented with a progressively enlarging mass in the posterior thorax. The physical examination revealed a solid, irregular, painful mass on palpation. Doppler ultrasonography and high-resolution computed tomography (CT) scan revealed a 60 × 38 mm hypoechoic tumor in the left paraspinal thoracic area with a little vascularity with no adherence and invasion. Radical excisional surgery was performed. The histopathology findings were in line with myxofibrosarcoma except for CD34. He underwent high dose radiotherapy due to the reported not assessable margins at one side. The patient was asymptomatic and recurrent free in the 12 months follow up assessment. It was the first known case of the non-metastatic intermediate grade of myxofibrosarcoma in the thorax. Due to its deceptive findings, myxofibrosarcoma should always be considered in the assessment of chest wall tumors.
No takes yet. Share an insight, caveat, or question.
Aalami et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: